High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia

Lafaurie, M.; Lapalu, J.; Raffoux, E.
November 2010
Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p150
Academic Journal
In this study, the authors sought to determine the efficacy of antifungal agents for preventing breakthrough invasive aspergillosis (IA) in a cohort of patients with persistent fever and neutropenia who received empirical antifungal therapy. Caspofungin was the most prescribed antifungal agent, followed by liposomal amphotericin B. Six of 49 patients developed possible or probable IA, all of whom were on caspofungin. These results suggest a high rate of breakthrough IA in patients receiving caspofungin.


Related Articles

  • Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies. Steinbach, William J. // Current Drug Targets - Infectious Disorders;Sep2005, Vol. 5 Issue 3, p203 

    The optimal therapy for invasive aspergillosis (IA) is unknown, and there is little agreement on the exact antifungal management of IA. The previously stagnant landscape of antifungal choices for IA is rapidly changing with newer antifungals and newer targets. While amphotericin B has...

  • Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos? G., ANA MARÍA RIVAS; CARDONA-CASTRO, NORA // CES Medicina;2009, Vol. 23 Issue 1, p61 

    The prevalence of invasive fungal infections has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. For many years, amphotericin B and flucytosine were the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal...

  • Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Kleinberg, M. // Medical Mycology;Feb2005 Supplement 1, Vol. 43, p289 

    Aspergillosis is a potentially lethal infection of immunocompromised patients. Until 10 years ago, antifungal therapy was largely limited to amphotericin B deoxycholate. Perceived poor response rates and inherent toxicities with amphotericin B deoxycholate were a major stimulus for the...

  • Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Wang, J. L.; Chang, C. H.; Young-Xu, Y. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p152 

    In this meta-analysis, the authors evaluated the hepatotoxicity of antifungal agents in the treatment of invasive fungal infections, and examined whether hepatotoxicity was the cause of treatment discontinuation and study withdrawal. The risk of hepatotoxicity was higher in patients with...

  • Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. Riedel, Amy; Choe, Lan; Inciardi, John; Yuen, Courtney; Martin, Thomas; Guglielmo, B Joseph // BMC Infectious Diseases;2007, Vol. 7 Issue 1, p70 

    Background: In August 2002, the antifungal prophylaxis algorithm for neutropenic hematology/oncology (NHO) patients at the Medical Center was changed from conventional amphotericin (AMB) to an azole (AZ) based regimen (fluconazole [FLU] in low-risk and voriconazole [VOR] in high-risk patients)....

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S. B.; Chapuis, F.; Decullier, E.; Revol, B. G. P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2006, Vol. 25 Issue 2, p138 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...

  • The new antifungals-- safe and effective. Gallagher, Jason C.; Kauffman, Carol A.; Perfect, John // Patient Care;Jun2005, Vol. 39 Issue 6, p41 

    Discusses the advantages and indications of several antifungal agents. Reasons that the increased incidence of fungal infections shows no sign of decline or leveling of; Alternatives to amphotericin B deoxycholate; Infections caused by fungi, eukaryotes that are more complex organisms than...

  • Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Wingard, John R. // Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS38 

    Persistent or recurrent unexplained fever in neutropenic patients receiving antibiotics can be caused by invasive fungal infections, which are often difficult to diagnose. Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency...

  • Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Denning, David W.; Drusano, George L. // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p673 

    The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmaco dynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics